University Consortium R&D Platform Files IPO Prospectus: Bridging Academia and Industry in Medical Innovation

In recent years, with the“University Economy”With rapid development, an increasing number of universities have begun to engage in scientific research, focusing primarily on the healthcare sector, which boasts substantial market demand and promising R&D prospects.

According to the "2019 Annual Report on the Transformation of Scientific and Technological Achievements in China (Colleges, Universities, and Research Institutes)," in 2018, the contract value of scientific and technological achievements transformed by 3,200 colleges, universities, and research institutes in China through transfer, licensing, and equity investment reachedRMB 17.73 billion, representing a year-on-year increase of 52.2%, among which32 institutions had total contract values for technology transfer exceeding RMB 100 million., representing a year-on-year increase of 14.3%.

It is worth noting that among these 32 projects with funding exceeding RMB 100 million, 12 were medical-related, a figure that strongly validates the current enthusiasm of universities for research in the healthcare sector. However, for scientific research, enthusiasm is merely a prerequisite,A profound understanding of research and an efficient research model are the true core.

These two points align precisely with the inherent advantages possessed by universities.On the one hand, universities possess a strong foundation in basic research, is the source of the innovation ecosystem;On the other hand, universities can effectively promote interdisciplinary integration., in the current medical field, the low-hanging fruits have been largely harvested, leaving only the tough nuts to crack, and future opportunities will undoubtedly stem from interdisciplinary innovation.

Therefore, as the “main force” in basic research and the “vital contingent” driving major scientific and technological breakthroughs, universities will inevitably shoulder greater responsibilities for scientific innovation in the medical field in the future.But how can universities better leverage their research advantages? How should the deep integration of industry, academia, and research be advanced? Can interdisciplinary collaboration among universities find an optimal path?

Guided by this problem-oriented approach,Peking University, Beijing University of Chemical Technology, Beijing University of Technology, Tianjin UniversityResearchers from certain departments andChinese Academy of SciencesJoint Research by Selected Scientific TeamsBeijing Zhonglian R&DCo-founded by Technology Co., Ltd."Joint R&D Platform of Universities"。

This R&D platform differs from domestic research institutions and universities."Going It Alone"The current state of scientific research involves truly integrating the research strengths of major universities and the Chinese Academy of Sciences to address, through interdisciplinary collaboration, the technological challenges faced by domestic medical device enterprises in achieving localization of consumables and product innovation and upgrading. This effort aims to incubate a batch of medical device products in China that possess internationally leading technologies and price competitiveness.

To better promote innovation and commercialization, the platform has drawn on Germany's“Fraunhofer Society”Mode. This isEurope's Largest Applied Science Research Institution, currently comprising 81 independent research institutes, with over 29,000 employees and an annual budget of up to €2 billion.

The Fraunhofer Society is positioned in applied research, with a deep focus on key technologies relevant to the future and the development of commercial outcomes.The Association has effectively built a “bridge” between academic research and industrial production., closely linking universities engaged in basic research with enterprises involved in product development to form a synergistic force that jointly drives industrial innovation and translation.

Currently, the “University Joint R&D Platform” has incubated multiple innovative achievements, with several research projects also underway, primarily focusing onNovel Polymeric BiomaterialsandStem Cell Fieldas the main focus, they basically all have broad market application prospects and economic value.

The following are the highlighted R&D projects compiled from the platform:

(1) Project Overview: The device features a core component—the dialysate regeneration unit—and is only the size of a waist pack, weighing just 2 kilograms. On one hand, it enables continuous treatment to enhance therapeutic efficacy; on the other hand, it improves patients’ quality of life by allowing optimized peritoneal dialysis anytime and anywhere, free from constraints of time and location, while also reducing medical costs such as those for peritoneal dialysis fluids.

(2) Project Progress: A prototype is currently available, and clinical trials are about to commence.

(1) Project Overview: Currently, implantable devices, indwelling medical devices, and extracorporeal circulation devices used in hospital treatments generally require substantial amounts of heparin for anticoagulation. However, excessive heparin use can easily lead to localized bleeding and other adverse effects in the human body. To avoid or reduce heparin usage, this new material incorporates a novel superhydrophilic coating along with other composite anticoagulant coatings, significantly improving the blood compatibility of the material.

(2) Project Progress: Currently in the mid-stage of scientific research.

(1) Project Overview: The laser fiber optic sleeve (a cylinder with cooling and scattering functions, approximately 2–3 mm in diameter) is an accessory for laser ablation surgery of brain tumors. It is implanted into the core area of the target region using stereotactic technology. The cooler reduces carbonization caused by the laser, prolongs the duration of laser action, and increases the range of thermal absorption in the tissue. The scatterer ensures uniform irradiation of the target tissue, achieving uniform and symmetric energy distribution within the tissue. Meanwhile, this product serves as a domestically produced alternative, offering lower costs, with pricing at only one-tenth that of imported products.

(2) Project Progress: The final product has been successfully manufactured and has been effectively utilized in clinical surgeries. It is now ready for direct application for registration certification and mass production.

(1) Project Highlights: Autogenous arteriovenous fistula is recognized as the optimal vascular access for patients undergoing maintenance hemodialysis. However, due to long-term use and repeated punctures, it is prone to causing local injuries and complications, which severely affect dialysis efficacy and patients' quality of life. Consequently, tunneled cuffed catheters (TCCs) are now widely used globally. Currently, the TCCs commonly used in clinical practice in China are all imported brands from the United States, with the manufacturing challenge lying in the production of the peel-away sheath. This product has successfully achieved domestic substitution in China, offering a lower cost with a price set at only half that of imported products.

(2) Project Progress: Currently in the late stage of research and development, nearing completion of the final product.

(1) Project Highlights: Composed of a blend of biodegradable polymer materials, single-use medical devices made from this material do not require incineration after use. They can be fully degraded by microorganisms through composting, achieving environmental protection and energy conservation goals while preventing illegal reuse.

The cost is relatively low, essentially approaching the current pricing of standard disposable medical consumables.

(2) Project Progress: Syringes, cervical dilators, and other products have been successfully manufactured and are ready for mass production.

(1) Project Highlights: Stem cell therapy is currently widely used for osteoarthritis, diabetes, brain diseases, cardiovascular diseases, and other conditions. Stem cell transplantation therapies for these organs rely on biodegradable biological scaffolds. This product is a functionalized nanofiber scaffold composed of biocompatible composite materials, designed to enhance stem cell adhesion and proliferation. It effectively restricts cell migration from the injury site, maintains the stemness of the cells, and promotes the differentiation and maturation of organ-specific cells.

(2) Project Progress: Currently in the mid-term stage of scientific research.

Zhonglian R&D is a company dedicated to proposing product design requirements to scientific research teams, liaising with hospitals to address clinical needs and manage clinical trials, and facilitating corporate partnerships. Its team members possess extensive experience in selling products across multiple hospital departments, enabling them to deeply understand physicians’ needs and the product upgrade requirements of various manufacturers, thereby providing clear direction for innovation.